Receptor activator of NF-kappaB ligand (RANKL) is the master osteoclastogenic cytokine, responsible for osteoclast (OC) differentiation, activation, and survival. Interaction of RANKL with its receptor, RANK, activates the NF-kB pathway in macrophage-lineage OC progenitors. Mice deficient in RANKL, RANK, or both the p50 and p52 subunits of NF-kB lack OCs, establishing the central role for the RANKL/RANK/NF-kB pathway of osteoclastogenesis (Ocg). NF-kB inducing kinase (NIK) is a serine/threonine non-receptor kinase in the MAP3K family thought to link a number of nokn-kinase receptors with the NF-kB pathway. NIK directly interacts with TRAFs, adaptor molecules which bind to many receptors, including RANK, and with IKB kinases (IKKs). The IKKs are substrates of, and activated by NIK. Activated IKKs phosphorylate IkBalpha, leading to its degradation and release of activated NF-kB, which translocates to the nucleus. NF-kB then stimulates transcription of genes bearing kB elements in their promoters. They discovered that NF-kB activation, in response to RANKL, is intact in NIK-deficient OC precursors. On the other hand, mice lacking NIK fail to generate OCs in vitro and are resistant to stimulated Ocg in vivo. Thus, osteoclastogenic signals exist which are distinct from NF-KB but are nonetheless dependent on NIK. They hypothesize: 1. Specific motifs within NIK regulate Ocg. 2. NIK directly binds essential osteoclastogenic components of the RANK signaling pathway.
The specific aims are to: 1. Identify motifs within NIK which regulate Ocg. 2. Identify components of the RANK signaling pathway which directly interact with NIK. To accomplish these aims, they will utilize expertise in retroviral expression and OC biology, as well as establish the new technique of yeast 2-hybrid screens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08AR047846-01
Application #
6361733
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Sharrock, William J
Project Start
2001-07-11
Project End
2006-06-30
Budget Start
2001-07-11
Budget End
2002-06-30
Support Year
1
Fiscal Year
2001
Total Cost
$107,244
Indirect Cost
Name
Barnes-Jewish Hospital
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63110
Vaira, Sergio; Alhawagri, Muhammad; Anwisye, Imani et al. (2008) RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 118:2088-97
Vaira, Sergio; Johnson, Trevor; Hirbe, Angela C et al. (2008) RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A 105:3897-902
Mao, Dailing; Epple, Holly; Uthgenannt, Brian et al. (2006) PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 116:2869-79
Aya, Kunihiko; Alhawagri, Muhammad; Hagen-Stapleton, Amanda et al. (2005) NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 115:1848-54
Zhao, Haibo; Kitaura, Hideki; Sands, Mark S et al. (2005) Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res 20:2116-23
Novack, Deborah Veis; Yin, Li; Hagen-Stapleton, Amanda et al. (2003) The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198:771-81